期刊文献+

碘钠同向转运体在新疆维吾尔族甲状腺乳头状癌中的表达及其临床意义 被引量:1

The expression and clinical significance of NIS in Xinjiang Uygur papillary adenocarcinoma
下载PDF
导出
摘要 目的研究钠碘同向转运体(NIS)在新疆维吾尔族甲状腺乳头状癌组织标本及转移淋巴结组织中的表达及其临床意义。方法选取手术切除后经临床病理证实的新疆维吾尔族甲状腺乳头状癌存档标本72例,采用免疫组织化学检测NIS在甲状腺癌组织、癌旁组织以及转移淋巴结组织中的表达,分析NIS在甲状腺癌组织中的分布特点及其与临床病理各参数间的相互关系。结果 (1)甲状腺乳头状癌组织中NIS表达阳性率为80.56%,在癌旁正常甲状腺组织中的NIS阳性表达率为30.56%,差异有统计学意义(P<0.05);(2)Ⅰ、Ⅱ期甲状腺癌组织中NIS表达阳性率为87.88%,Ⅲ、Ⅳ期甲状腺癌组织中NIS表达阳性率为74.36%,随着临床分期的递增,甲状腺癌组织中NIS表达阳性率出现降低趋势,但差异无统计学意义(P>0.05);(3)在有淋巴结转移和无淋巴结转移的甲状腺乳头状癌患者中NIS表达阳性率分别为68.97%和42.86%,差异有统计学意义(P<0.05);(4)在肿瘤直径≤2cm和>2cm的甲状腺乳头状癌组织中NIS表达阳性率分别为93.02%和62.07%,差异有统计学意义(P<0.05)。结论新疆维吾尔族甲状腺乳头状癌组织中NIS的表达随着临床分期增加而逐渐降低,在有淋巴结转移患者中NIS的表达显著增加,同时随着瘤体体积的增大NIS的表达显著下降。 Objective To analyze the clinical significance of sodium/iodide symporter (NIS) by investigating the expression of which in tissue of papillary adenocarcinoma and metastatic lymphonodes of Xinjiang Uygur nationality. Methods Seventy two cases of paraffin slices made from Xinjiang Uygur patients con firmed to be papillary adenocarcinoma by clinical pathology were collected and tested the expression of NIS in tissue of carcinoma, beside the carcinoma and metastatic lymphonodes by means of immunohistochemistry, analyzed the distribution and the correlation with pathologic parameters. Results expression rate of NIS in tissue of carcinoma, beside the carcinoma were 80.56%, 30. respectively; (2) The expression of NIS in stage Ⅰ , Ⅱ was 87.87%, and which was 74. (1) 6H 36% The positive and 56.94% in sta IV. With the clinical stage increments, in thyroid cancer tissue ,the expression rate of NIS decrease ge Ⅲ, d, but the difference was not statistically significant (P 〉0.05) ; (3) The positive rates of NIS expression in pa- tients with papillary thyroid carcinoma with lymph node metastasis and without lymph node metastasis- were 68.97% and 42.86%, the difference was statistically significant (P 〈0.05). (4) The positive rates of NIS expression in thyroid papillary carcinoma with tumor diameter≤2 cm and 〉2 cm were 93.02% and 62.06%, the difference was statistically significant (P 〈0. 05). Conclusion The expression of NIS in pa- pillary adenocarcinoma in Xinjiang Uygur patients deceases with the growth of disease stage and diameter of the tumor, apparently increases in patients with lymphonodes metastases.
出处 《新疆医科大学学报》 CAS 2012年第7期891-894,共4页 Journal of Xinjiang Medical University
基金 乌鲁木齐市科学技术项目(Y09231001)
关键词 钠碘同向转运体(NIS) 甲状腺乳头状癌 维吾尔族 sodium/iodide symporter (NIS) papillary adenocarcinoma Uygur
  • 相关文献

参考文献10

  • 1柳卫.钠/碘同向转运体[J].国外医学(放射医学核医学分册),2001,25(2):49-52. 被引量:2
  • 2张恒,朱精强,唐颖,李志辉,魏涛.NIS蛋白表达对甲状腺癌诊断及^(131)I疗效预测的相关性研究[J].中国普外基础与临床杂志,2007,14(5):554-559. 被引量:5
  • 3陈恺,秦永德,巴雅,谢彬,李肖红,刘立水,王塞岗.SPECT/CT融合显像在分化型甲状腺癌术后^(131)I治疗随访中的研究[J].新疆医科大学学报,2010,33(10):1239-1241. 被引量:6
  • 4Laeroix L, Pourcher T, Magnon C, et al. Expression of the apicaliodide transporter in human thyroid tissues: a comparison study with other iodide transporters [J]. J Clin Endocrinol Metab, 2004,89(3) :1423-1428.
  • 5Caillou B, Troalen F, Baudin E, et al. Na+/I-symporter dis- tribution in human thyroid tissues: an immunohistochemical study[J]. J Clin Endocr Metab, 1998,83(11) :4102.
  • 6Napolitano G, Montani V, Giuliani C, et al. Transforming growth factorbetal down-regulation of major histocompatibili- ty complex class I in thyrocytes: coordinate regulation of two separate elements by thyroid specific as well as ubiquitous transcriptionfactors[J]. Mol Endocr, 2000, 14(4) :486-505.
  • 7Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide Symporter(NIS) characterization, regulation, and medical sig- nificance[J]. Endocr Rev, 2003, 24(1) :48-77.
  • 8Postiglione MP, Parlato R, Rodriguez-Mallon A, et al. Role of the thyroid- stimulating hormone receptor signaling in devel- opment and differentiation of the thyroid gland[J]. Proc Natl Acad Sci USA, 2002, 99(24):15462-15467.
  • 9Zidan J, Karen D, Stein M, et al. Pure versus follicular variant of papillary papillary adenocarcinoma:clinical features, prognostic fac tots, treatment, and survival[J]. Cancer,2003,97(5):1181.
  • 10Chang HY, Lin JD, Chou SC, et al. Clinical presentations and out comes of surgical treatment of follicular variant of the papillarypapillary adenoearcinomas [J]. Jpn J Clin Oneol, 2006,36(11) :688.

二级参考文献76

  • 1姚榛祥.我国甲状腺外科的展示[J].中国普外基础与临床杂志,2004,11(6):473-476. 被引量:3
  • 2康增寿.^(131)I治疗甲状腺癌[J].中国普外基础与临床杂志,2006,13(3):252-253. 被引量:24
  • 3Parthasarathy KL,Crawford ES.Treatment of thyroid carcinoma:emphasis on high dose 131I outpatient therapy[J].Nucl Med Technol,2002,30:165-171.
  • 4Sherman SI.Thyroid carcinoma[J].Lancet,2003,36:501-511.
  • 5Cholewinski SP,Yoo KS,Klieger PS,et al.Absence of t hyroid stunning after diagnostic whole body scanning with 185 MBq 131I[J].J Nucl Med,2000,41(7):1198-1202.
  • 6Schmidt D,Szikszai A,Linke R,et al.Impact of 131I SPECT/Spiral CT on nodal staging of differntiated thyriod carcinoma at the first radioblation[J].J Nucl Med,2009,50(1):18-23.
  • 7Mazzaferri ML,Jiang SM.Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J].Am J Med,1994,97:418-428.
  • 8Sherman SI,Brierley JD,Sperling M,et al.Prospective multicenter study of thyroid carcinoma treatment[J].Cancer,1998,83:1012-1021.
  • 9Pacini F,Schlumberger M,Dralle H,et al.European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium[J].Eur J Endocrinol,2006,154:787-803.
  • 10Even-Sapir E,Keidar Z,Sachs J,et al.The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms[J].J Nucl Med,2001,42:998-1004.

共引文献10

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部